If We Nip It In The Bud Is This The Future Of Cure and Improved Survival Rates for Myeloma ? Do Not Miss The Cure Panel Featuring Dr. Ghobrial

Now that the program has aired you can listen to a rebroadcast of this CAN NOT MISS CURE PANEL featuring Dr. Ghobrial of the Dana Farber Cancer Institute.  She discussed the subject of Early Treatment of Myeloma  in a patient friendly manner at the February 12th  Myeloma Cure Panel.   You can listen to a rebroadcast of the program if you CLICK HERE.


I had the opportunity to be at ASH (American Society of Hematology)  in San Francisco and went to one of the more research oriented presentations which was moderated by Dr. Gareth Morgan and featured a presentation by Dr. Irene Ghobrial of the Dana Farber Cancer Center.  Dr. Ghobrial discussed the effect the bone marrow micro-environment  has on the progression of multiple myeloma, and ways to make this micro-environment inhospitable to tumor growth.  Her research has shown this micro-evironment has been modified in mice with exceptional results.  Translated to success in  human trials, this could be a the potential CURE.  To view a link to the abstract CLICK HERE.  Just be aware that this link may make your eyes glaze over.  Dr. Ghobrial will be dscussing this in a patient friendly manner at the February 12th  Myeloma Cure Panel which will broadcast at 6:00pm EST.  The broadcast is titled Early Treatment of Myeloma with Dr. Irene Ghobrial, and you can get the details on how to listen live or enter your questions for the doctor is you CLICK HERE.  If you want to call in to listen you can call in a few minutes prior to the broadcast at the number (718) 664-6574 or listen on line by  CLICKING HERE.

For me this was one of the most exciting revelations from the ASH meeting.  Most other presentations talked about new drugs used at relapse which may give you one or two years of added life, but this was different, this was the possibility of cure for all high risk MGUS and Smoldering patients.  With the potential to prevent relapse after initial therapy or after relapse. This I believe it is the future of myeloma treatment and cure, and to say this was a can’t miss panel would be a huge understatement.

About the Author